Literature DB >> 8050088

Alterations of serum lipids and lipoproteins in breast cancer.

E Kökoğlu1, I Karaarslan, H M Karaarslan, H Baloğlu.   

Abstract

Serum triglycerides, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very-low density lipoprotein (VLDL) cholesterol levels were quantified in Stage I and Stage IV breast cancer patients in order to evaluate the changes in serum lipids and lipoproteins in the early and advanced stages of the disease. When compared with data from age-matched healthy females, fasting serum triglycerides and VLDL cholesterol levels were found to be significantly increased and HDL cholesterol levels significantly decreased in patients with breast cancer. Furthermore, a significant increase in triglycerides and VLDL cholesterol and decreases in total, HDL and LDL cholesterol levels were demonstrated in patients with Stage IV disease when compared to those with Stage I breast cancer. No significant difference was found in total and LDL cholesterol between Stage I breast cancer patients and healthy controls.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050088     DOI: 10.1016/0304-3835(94)90008-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  25 in total

Review 1.  Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.

Authors:  Amani Batarseh; Vassilios Papadopoulos
Journal:  Mol Cell Endocrinol       Date:  2010-06-30       Impact factor: 4.102

2.  A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer.

Authors:  Geoffrey C Kabat; Mimi Kim; Rowan T Chlebowski; Janu Khandekar; Marcia G Ko; Anne McTiernan; Marian L Neuhouser; Donna R Parker; James M Shikany; Marcia L Stefanick; Cynthia A Thomson; Thomas E Rohan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-30       Impact factor: 4.254

3.  Metabolic effects of pioglitazone in chemically-induced mammary carcinogenesis in rats.

Authors:  Bianka Bojková; Miroslava Garajová; Martin Péč; Peter Kubatka; Karol Kajo; Marián Mokáň; Monika Kassayová; Peter Orendáš; Terézia Kisková; Eva Ahlersová; Ivan Ahlers
Journal:  Pathol Oncol Res       Date:  2011-06-07       Impact factor: 3.201

4.  Apolipoprotein E genetic polymorphism, serum lipoprotein levels and breast cancer risk: A case-control study.

Authors:  Gabriela Herrmann Cibeira; Juliana Giacomazzi; Ernestina Aguiar; Silvana Schneider; Betina Ettrich; Caroline Isoppo DE Souza; Suzi Camey; Maira Caleffi; Bernardete Weber; Patricia Ashton-Prolla; Emilio Hideyuki Moriguchi
Journal:  Mol Clin Oncol       Date:  2014-08-01

5.  Correlation Between Obesity and High Density Lipoprotein Cholesterol (HDL-C) in Breast Cancer Patients of Southern Rajasthan.

Authors:  Padmanabh Inamdar; Garima Mehta
Journal:  Indian J Surg Oncol       Date:  2011-05-06

6.  Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic.

Authors:  Kelly Shum; Amber Solivan; Parham Parto; Nichole Polin; Eiman Jahangir
Journal:  Ochsner J       Date:  2016

7.  HDL-cholesterol and incidence of breast cancer in the ARIC cohort study.

Authors:  Anna M Kucharska-Newton; Wayne D Rosamond; Pamela J Mink; Anthony J Alberg; Eyal Shahar; Aaron R Folsom
Journal:  Ann Epidemiol       Date:  2008-09       Impact factor: 3.797

8.  Alterations of serum cholesterol and serum lipoprotein in breast cancer of women.

Authors:  Kiran Hasija; Hardeep K Bagga
Journal:  Indian J Clin Biochem       Date:  2005-01

Review 9.  Clinically Relevant Physical Benefits of Exercise Interventions in Breast Cancer Survivors.

Authors:  Amy A Kirkham; Kelcey A Bland; Sarah Sayyari; Kristin L Campbell; Margot K Davis
Journal:  Curr Oncol Rep       Date:  2016-02       Impact factor: 5.075

10.  Total cholesterol and triglyceride levels in patients with breast cancer.

Authors:  Umesh Kapil; Ajeet Singh Bhadoria; Neha Sareen; Preeti Singh; Sada N Dwivedi
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.